Locations:
Search IconSearch
March 28, 2017/Neurosciences/Outcomes

Botulinum Toxin in Movement Disorders: Two Outcomes Snapshots

Most patients report relief from intractable spasms

16-NEU-2805-Botox-650×450

Chemodenervation therapy using botulinum toxin offers a low-risk option for often painful and disabling movement disorders that are difficult to treat. Success rates for improving symptoms merit trying this treatment before embarking on a surgical course of action.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Outcomes data from the use of this strategy in Cleveland Clinic’s Center for Neurological Restoration in 2015 reveal that a variety of difficult-to-treat movement disorders are amenable to improvement. Injected directly into involved muscles, botulinum toxin (Botox®, Dysport®, Myobloc® and Xeomin®) tends to be most effective in treating spastic disorders involving only a few muscle groups. Most patients require repeat injections every three to four months as the effects of the toxin wears off.

Cervical dystonia

Of the 126 patients treated with botulinum toxin in 2015 at Cleveland Clinic for cervical dystonia (spasmodic torticollis) — most of whom had complex presentations — 62 percent rated their condition as improved on the Patient Global Impression of Improvement (PGI-I) questionnaire (see table below). This response rate was achieved despite the high acuity of patients and the fact that a significant portion of cases had failed to respond to botulinum toxin injections from other providers. Fewer than 20 percent of patients rated their condition as worse following treatment, with most rating it as minimally worse.

16-NEU-2805-Inset1

Other movement disorders, pain

Other movement disorders, including other forms of dystonia, hemifacial spasm and spasticity, can also be treated with botulinum toxin, as can intractable migraine.

Out of all patients treated with chemodenervation at Cleveland Clinic in 2015 (N = 237), including those with medication-resistant migraine, hemifacial spasms and dystonia, more than half (53 percent) rated their condition as improved on the PGI-I questionnaire (see table below). Of the approximately 20 percent who reported their condition as worse, most rated the worsening as minimal.

Advertisement

16-NEU-2805-Inset2

More outcomes data online

Cleveland Clinic systematically collects and reports quality and outcomes measures for other treatments for movement disorders, including spinal cord stimulation and deep brain stimulation. These data, as well as outcomes for the full range of neurological disorders treated at Cleveland Clinic, can be accessed online in the 2015 Neurological Institute Outcomes Book.

Advertisement

Related Articles

16-NEU-2800-Kubu-101058161-650×450
What Do Patients Want from DBS for Parkinson’s Disease?

New study advances understanding of patient-defined goals

photo of a man sleeping at a desk, with a podcast icon overlay
March 15, 2024/Neurosciences/Podcast
Diagnosis and Management of Idiopathic Hypersomnia (Podcast)

Testing options and therapies are expanding for this poorly understood sleep disorder

illustration of an alzheimer brain and a packet of sildenafil pills
March 11, 2024/Neurosciences/Research
Sildenafil as an Alzheimer’s Candidate Drug: Further Support From Insurance Database and Mechanistic Studies

Real-world claims data and tissue culture studies set the stage for randomized clinical testing

brain scan showing perimesencephalic subarachnoid hemorrhage
Study Supports Less-Strict Monitoring for Nonaneurysmal Perimesencephalic SAH Without Hydrocephalus

Digital subtraction angiography remains central to assessment of ‘benign’ PMSAH

illustrated brain with the letters "AI" on a computer circuit board
As AI Tools Emerge, Be Proactive and Engaged to Shape Their Development

Cleveland Clinic neuromuscular specialist shares insights on AI in his field and beyond

histology image of a gray matter lesion in a multiple sclerosis brain
Study Suggests Protective Role for Microglia at Borders of Gray Matter Lesions in Progressive MS

Findings challenge dogma that microglia are exclusively destructive regardless of location in brain

series of digital-looking brain icons with a podcast button overlay on top
March 1, 2024/Neurosciences/Podcast
Harnessing the Power of AI in Medicine (Podcast)

Neurology is especially well positioned for opportunities to enhance clinical care and medical training

illustration of a neuron affected by multiple sclerosis
Clinical Trials in Progressive MS: An Assessment of Advances and Remaining Challenges

New review distills insights from studies over the past decade

Ad